COVID-19 Research: Ginger-Derived Compounds May Hold Key to Novel Therapeutics

Strategic Insights -

Researchers from the Graduate University of Advanced Technology in Iran have made a significant discovery in the fight against COVID-19. By analyzing the inhibitory effects of major phenolic compounds from ginger, including gingerol, paradol, and shogaol, against the main protease (Mpro) of SARS-CoV-2, they found that shogaol exhibited the strongest binding affinity (- 9.95 kcal/mol) and formed stable interactions with key active site residues. Molecular dynamics simulations confirmed the stable binding behavior of the shogaol-Mpro complex. These findings suggest that ginger-derived phenolic compounds, particularly shogaol, may serve as promising candidates for the development of novel therapeutics targeting COVID-19 main protease.

Key Takeaways:

  • The study investigated the inhibitory effects of ginger-derived phenolic compounds against the main protease (Mpro) of SARS-CoV-2.
  • Shogaol exhibited the strongest binding affinity (- 9.95 kcal/mol) among the tested compounds.
  • Molecular dynamics simulations confirmed the stable binding behavior of the shogaol-Mpro complex.
  • The findings suggest that ginger-derived phenolic compounds may serve as promising candidates for the development of novel therapeutics targeting COVID-19 main protease.
  • The study highlights the potential of natural compounds in the development of anti-COVID-19 therapeutics.
  • The Graduate University of Advanced Technology in Iran conducted the research, with Mehdi Yoosefian, Arefeh Esmaeili, and Kasim Sakran Abass as the authors.

Statistics:

  • The study found that shogaol exhibited a binding affinity of - 9.95 kcal/mol against the main protease (Mpro) of SARS-CoV-2.
  • Molecular dynamics simulations were performed for 500 ns using the GROMACS software.
  • The study reported favorable ADMET characteristics and a low toxicity profile for all selected compounds.
  • The research concluded that ginger-derived phenolic compounds, particularly shogaol, may serve as promising candidates for the development of novel therapeutics targeting COVID-19 main protease.

Sources:

  • Pharmacokinetic, toxicological, and molecular interaction assessment of ginger-derived phenolics for SARS-CoV-2 main protease Inhibition. Scientific Reports, 2025;15(1):27390. Nature Portfolio, Heidelberger Platz 3, Berlin, 14197, Germany. (Nature Publishing Group - www.nature.com/; Scientific Reports - www.nature.com/srep/)
  • NewsRx. New Findings from Graduate University of Advanced Technology in the Area of COVID-19 Described (Pharmacokinetic, toxicological, and molecular interaction assessment of ginger-derived phenolics for SARS-CoV-2 main protease Inhibition). Medical Letter on the CDC & FDA. August 17, 2025; p 76.